New Anti-Virals Against Wild-Type and Lamivudine-Resistant Hepatitis B Virus

  • Naoya Kato
  • Suzane Kioko Ono-Nita
  • Masao Omata
Conference paper


Background:Chronic infection with hepatitis B virus (HBV) remains among the ten most common causes of death worldwide. Lamivudine became the first approved oral therapy for the treatment of HBV. Although lamivudine treatment rapidly reduces HBV DNA levels and improves liver histology, the emergence of resistant HBV with L180M and/or M204V/I (YMDD motif mutations) in the polymerase gene following long-term treatment is becoming an important clinical problem. Thus, there is a pressing need to develop new anti-virais and new strategies to treat lamivudine-resistant HBV. Recently, we have established thein vitrofull-length HBV DNA transfection system that facilitates the testing of antivirals against HBV mutants. Using this system, we have investigated the susceptibility of wild-type and lamivudine-resistant HBV to new anti-virais.

Methods:Replication fitness and susceptibility of wild-type and lamivudineresistant HBV (M204I, M204V, and L180M/M204V) to 21 anti-virais was investigated by transient transfection of full-length HBV DNA into human hepatoma cells (HuH-7). HBV DNA replication was monitored by Southern blot hybridization, and effective concentration required to reduce HBV replication by 50% (EC50) was determined

Results:Although the replication competency of M204I and M204V was markedly decreased compared to that of wild-type HBV, L180M/M204V restored replication competence. Of 21 anti-virais, 13 anti-virais were effective against wild-type HBV, and 6 anti-virais (entecavir, MCC-478, L-D4FC, clevudine, emtricitabine, lobucavir) inhibited wild-type HBV replication more than lamivudine. However, only 4 anti-virais (entecavir, MCC-478, adefovir, lobucavir) were effective against all HBV mutants. Moreover, a higher dose of anti-viral was necessary to inhibit L180M/M204V compared to M204V.

Conclusion: Our study identified anti-virais with stronger potency than lamivudine against wild-type HBV and with potency against lamivudine-resistant HBV. They appear to be excellent candidates for the future treatment of HBV infection. L180M mutation of HBV polymerase not only restores the replication competence of M204V, but also increases drug resistance.


Adefovir Dipivoxil YMDD Motif Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan K-H, Carrilho FJ, Omata M. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 1999;29:939–945.PubMedCrossRefGoogle Scholar
  2. 2.
    Ono-Nita SK, Kato N, Shiratori Y, Lan K-H, Yoshida H, Carrilho FJ, Omata M. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999;103:1635–1640.PubMedCrossRefGoogle Scholar
  3. 3.
    Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001;107: 449–455.PubMedCrossRefGoogle Scholar
  4. 4.
    Ono-Nita SK, Kato N, Shiratori Y, Carrilho FJ, Omata M. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrob Agents Chemother 2002;46:2602–2605.PubMedCrossRefGoogle Scholar
  5. 5.
    Perrilo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129–134.CrossRefGoogle Scholar
  6. 6.
    Chang TT, Hadziyannis S, Cianciara J, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology 2002;36:300A.Google Scholar
  7. 7.
    Leung N, Gish RG, Wang C, Corey L, Sacks S, Fried M, Wright T, Huy T, Chan F, Rousseau FS. A randomized, double-blind, comparison of 3 doses of emtricitabine (FTC) in patients with chronic hepatitis B (CHB) given 48 weeks of treatment (FTCB102). Hepatology 2001;34:349A.Google Scholar

Copyright information

© Springer Japan 2004

Authors and Affiliations

  • Naoya Kato
    • 1
  • Suzane Kioko Ono-Nita
    • 1
  • Masao Omata
    • 1
  1. 1.Department of Gastroenterology, Graduate School of MedicineUniversity of TokyoJapan

Personalised recommendations